Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common sleep aid ease Parkinson's symptoms?

NCT ID NCT07375693

Symptom relief Sponsor: Bangladesh Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether taking 10 mg of melatonin daily for 12 weeks can reduce oxidative stress and improve symptoms in 70 people with mild-to-moderate Parkinson's disease who are already on levodopa. Participants will be randomly assigned to receive melatonin or a placebo, and researchers will measure blood markers of oxidative stress and inflammation, as well as symptom scores. The goal is to see if this widely available sleep supplement offers additional benefits beyond standard treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
melatonin
What this could lead to
If it works, this could point toward a simple, low-cost way to ease Parkinson's symptoms and slow disease progression by reducing oxidative stress.
What could go wrong
This is a small, early-phase trial with only 70 participants over 12 weeks. Melatonin is generally safe, but it may not provide meaningful symptom improvement or affect long-term disease course.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * diagnosesd Parkinson's disease patients taking levodopa * mild to moderate PD pt according to Hohen and Yahr staging, stage-I,II,III * age:\>45 years * both male and female Exclusion Criteria: * secondary causes of PD * Prior stereotactic surgery for PD * suffering from active malignancy * known hypersensitivity to melatonin * Patients taking anticonvulsants, OCP, DMARD * pt with autoimmune disease * pregnancy or lactating mother * has any clinically significant medical condition that could interfere with the subject's ability to safely participate in the study or to be followed

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bangladesh medical university

    Dhaka, Dhaka Division, 1212, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.